Andersen Disease (Type IV)
Overview
Plain-Language Overview
Andersen Disease (Type IV) is a rare inherited disorder that affects the body's ability to properly store and use glycogen, a form of stored sugar used for energy. It primarily impacts the liver and muscle tissues, leading to problems with energy production. People with this condition often experience muscle weakness, liver enlargement, and sometimes heart problems. The disease is caused by a defect in an enzyme that helps build the correct structure of glycogen, resulting in abnormal glycogen deposits. This abnormal storage can cause damage to affected organs and impair their function. The condition usually appears in infancy or early childhood and can vary in severity.
Clinical Definition
Andersen Disease (Type IV), also known as glycogen storage disease type IV (GSD IV), is a genetic disorder caused by mutations in the GBE1 gene encoding the glycogen branching enzyme. This enzyme deficiency leads to the accumulation of abnormal, poorly branched glycogen called polyglucosan bodies in tissues, primarily the liver, skeletal muscle, and cardiac muscle. The defective glycogen structure impairs normal energy metabolism and causes progressive organ dysfunction. Clinically, it presents with hepatosplenomegaly, progressive liver cirrhosis, muscle hypotonia, and sometimes cardiomyopathy. The disease is inherited in an autosomal recessive pattern and is significant due to its potential to cause liver failure and early mortality if untreated.
Inciting Event
No specific external trigger; disease onset is due to inherited enzyme deficiency.
Symptom onset often follows the period of rapid glycogen accumulation in early infancy.
Latency Period
Symptoms usually develop within the first 6 to 12 months of life after birth.
Progressive accumulation of abnormal glycogen leads to gradual symptom onset over months.
Diagnostic Delay
Early symptoms such as hepatomegaly and hypotonia are nonspecific and often misattributed to other metabolic or infectious diseases.
Lack of awareness of Andersen disease (Type IV glycogen storage disease) leads to delayed genetic testing.
Overlap with other glycogen storage diseases complicates early diagnosis without enzyme assay or genetic confirmation.
Clinical Presentation
Signs & Symptoms
Hepatomegaly with abdominal distension is a primary clinical feature.
Muscle weakness and hypotonia lead to delayed motor milestones.
Failure to thrive and poor feeding are common in infancy.
Respiratory difficulties may occur due to muscle involvement.
Jaundice and signs of liver dysfunction can be present.
History of Present Illness
Progressive hepatomegaly with abdominal distension is a common initial complaint.
Development of muscle weakness and hypotonia occurs as disease progresses.
Failure to thrive and feeding difficulties are frequently reported in affected infants.
Some patients develop cardiomyopathy and respiratory difficulties in advanced stages.
Past Medical History
No prior illnesses typically precede onset, but history may include poor growth or recurrent infections due to metabolic compromise.
Absence of prior metabolic or liver disease before symptom onset is common.
Family History
Positive family history of early childhood liver disease or unexplained infant death may be present.
Consanguineous parents increase risk of autosomal recessive inheritance of GBE1 mutations.
Siblings may have similar symptoms or confirmed diagnosis of Andersen disease.
Physical Exam Findings
Hepatomegaly due to glycogen accumulation in the liver is a hallmark finding.
Hypotonia and muscle weakness are common due to glycogen storage in muscle tissue.
Failure to thrive and growth retardation are often observed in affected infants.
Cardiomyopathy may be present in some cases due to glycogen deposition in cardiac muscle.
Protuberant abdomen from enlarged liver and possible ascites.
Diagnostic Workup
Diagnostic Criteria
Diagnosis of Andersen Disease (Type IV) is established by demonstrating deficient glycogen branching enzyme activity in liver or muscle biopsy samples. Histological examination reveals characteristic polyglucosan bodies with abnormal glycogen structure on periodic acid-Schiff (PAS) staining. Genetic testing confirming pathogenic mutations in the GBE1 gene provides definitive diagnosis. Clinical features such as hepatosplenomegaly, progressive liver dysfunction, and muscle weakness support the diagnosis. Liver biopsy showing cirrhosis with abnormal glycogen deposits is a key diagnostic finding.
Pathophysiology
Key Mechanisms
Deficiency of glycogen branching enzyme (GBE1) leads to accumulation of abnormal glycogen with fewer branch points, causing insoluble polyglucosan bodies.
Impaired glycogen branching results in poorly soluble glycogen deposits in liver, muscle, and heart tissues, disrupting cellular function.
Accumulation of polyglucosan bodies causes progressive organ dysfunction, especially in the liver and skeletal muscle.
The abnormal glycogen structure triggers hepatomegaly and muscle weakness due to cellular damage and energy metabolism impairment.
| Involvement | Details |
|---|---|
| Organs | Liver is the main organ affected, presenting with hepatomegaly, progressive fibrosis, and cirrhosis due to abnormal glycogen storage. |
Skeletal muscle may also be involved in some cases, leading to muscle weakness and hypotonia. | |
| Tissues | Liver tissue is primarily involved, showing accumulation of abnormal glycogen with fewer branches, leading to hepatocyte dysfunction and fibrosis. |
| Cells | Hepatocytes are the primary cells affected in Andersen disease due to defective glycogen branching enzyme leading to abnormal glycogen accumulation. |
Kupffer cells may become activated secondary to liver injury and contribute to inflammation and fibrosis. | |
| Chemical Mediators | Glycogen branching enzyme (GBE) deficiency caused by mutations in the GBE1 gene leads to accumulation of poorly branched glycogen. |
Fibrogenic cytokines such as transforming growth factor-beta (TGF-β) promote liver fibrosis in response to hepatocyte injury. |
Treatments
Pharmacological Treatments
Non-pharmacological Treatments
Liver transplantation is the definitive treatment to restore normal glycogen metabolism in Andersen disease (Type IV).
Supportive care includes management of cirrhosis complications such as portal hypertension and ascites.
Nutritional support with adequate caloric intake is important to prevent malnutrition and support growth.
Prevention
Pharmacological Prevention
No established pharmacological prevention exists; management focuses on supportive care.
Enzyme replacement therapy is not currently available for Andersen disease.
Preventive treatment of hypoglycemia with frequent feeding and glucose supplementation.
Non-pharmacological Prevention
Genetic counseling for families with known GBE1 mutations to prevent recurrence.
Regular monitoring of liver function and cardiac status to detect early complications.
Nutritional support including frequent meals to prevent hypoglycemia.
Early referral for liver transplantation evaluation in progressive cases.
Outcome & Complications
Complications
Liver failure from progressive hepatic damage is a major cause of morbidity.
Portal hypertension due to cirrhosis can lead to variceal bleeding.
Respiratory failure from muscle weakness and recurrent infections.
Hypoglycemia due to impaired glycogen metabolism.
| Short-term Sequelae | Long-term Sequelae |
|---|---|
|
|
Differential Diagnoses
Andersen Disease (Type IV) versus Pompe Disease (Type II Glycogen Storage Disease)
Andersen Disease (Type IV) | Pompe Disease (Type II Glycogen Storage Disease) |
|---|---|
Autosomal recessive inheritance caused by mutations in the GBE1 gene | Autosomal recessive inheritance due to mutations in the GAA gene |
Variable onset, often in infancy or childhood, with hepatomegaly and muscle weakness | Infantile onset with cardiomegaly and profound hypotonia |
Normal acid alpha-glucosidase with deficient glycogen branching enzyme activity | Elevated creatine kinase and acid alpha-glucosidase deficiency |
Abnormal glycogen structure with fewer branch points in liver and muscle | Lysosomal glycogen accumulation in cardiac and skeletal muscle |
Andersen Disease (Type IV) versus McArdle Disease (Type V Glycogen Storage Disease)
Andersen Disease (Type IV) | McArdle Disease (Type V Glycogen Storage Disease) |
|---|---|
Autosomal recessive due to mutations in the GBE1 gene | Autosomal recessive due to mutations in the PYGM gene |
Onset typically in infancy or early childhood with hepatomegaly | Onset in adolescence or early adulthood with exercise intolerance |
Normal muscle phosphorylase with deficient glycogen branching enzyme activity | Elevated serum creatine kinase and absent muscle phosphorylase activity |
Progressive hepatomegaly and liver dysfunction with possible muscle involvement | Exercise-induced muscle cramps and myoglobinuria without hepatomegaly |
Andersen Disease (Type IV) versus Cori Disease (Type III Glycogen Storage Disease)
Andersen Disease (Type IV) | Cori Disease (Type III Glycogen Storage Disease) |
|---|---|
Autosomal recessive due to mutations in the GBE1 gene | Autosomal recessive due to mutations in the AGL gene |
Deficiency of branching enzyme activity with abnormal glycogen structure | Deficiency of debranching enzyme activity with accumulation of limit dextrin |
Hepatomegaly with severe hypoglycemia and progressive liver fibrosis | Hepatomegaly with mild hypoglycemia and muscle weakness |
Reduced glycogen branching enzyme activity | Reduced amylo-1,6-glucosidase (debranching enzyme) activity |
Andersen Disease (Type IV) versus Glycogen Storage Disease Type I (Von Gierke Disease)
Andersen Disease (Type IV) | Glycogen Storage Disease Type I (Von Gierke Disease) |
|---|---|
Autosomal recessive due to mutations in the GBE1 gene | Autosomal recessive due to mutations in the G6PC gene |
Hypoglycemia with abnormal glycogen structure but less severe metabolic derangements | Severe fasting hypoglycemia with elevated lactate and uric acid |
Progressive liver disease with abnormal glycogen branching and fibrosis | Severe metabolic acidosis and hepatomegaly without abnormal glycogen branching |
Deficient glycogen branching enzyme activity | Deficient glucose-6-phosphatase activity |